Document is current
Any future updates will be listed below
-
Authors
Miller, Natalie J.
Kwan, Sharon W.
Leary, Jacob B.
Hippe, Daniel S.
McCamy, William
Veatch, Joshua R.
Hall, Evan T.
Monsky, Wayne L.
Bhatia, Shailender
-
Funding
Funding for this research was provided by:
Jacob Green Foundation
National Cancer Institute (P01 CA225517)
- License Information
-
More Information
Article History
Received: 7 May 2025
Accepted: 19 June 2025
First Online: 15 July 2025
Declarations
:
: JV reports equity interest in Lyell Immunopharma. EH reports research funding (to Institution) from Bristol Myers Squibb, NiKang Therapeutics, Neoleukin Therapeutics, Pfizer, ImCheck Therapeutics, Replimune, AstraZeneca, Gilead, Immunocore, Cullinan Oncology and Kezar Life Sciences; and consulting fees from Eisai Co. DH reports other research funding (to Institution) from GE Healthcare. SB reports research funding (to institution) from BMS, Merck, EMD Serono, Incyte, Checkmate Pharmaceuticals, TriSalus Life Sciences, and Agenus; honoraria and consulting fees from Incyte, BMS and Replimune; and travel support from Regeneron. NM, SK, JL, WM, and WLM report no disclosures.
